Minamiguchi, Hitoshi http://orcid.org/0000-0003-4450-0106
Fujita, Hiroyuki
Atsuta, Yoshiko
Asou, Norio
Sakura, Toru
Ueda, Yasunori
Sawa, Masashi
Dobashi, Nobuaki
Taniguchi, Yasuhiro
Suzuki, Rikio
Uchino, Yoshihito
Tomita, Akihiro
Tamaki, Shigehisa
Hagihara, Maki
Fujimaki, Katsumichi
Yanada, Masamitsu
Maeda, Yoshinobu
Iwanaga, Masako
Usui, Noriko
Kobayashi, Yukio http://orcid.org/0000-0003-2378-7865
Ohtake, Shigeki
Kiyoi, Hitoshi
Matsumura, Itaru
Miyazaki, Yasushi
Naoe, Tomoki
Takeshita, Akihiro http://orcid.org/0000-0001-7504-6677
,
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (23-004)
Japan Agency for Medical Research and Development (17ck0106251)
National Cancer Center Research and Development Fund (23-A-23, 26-A-24)
Article History
Received: 24 December 2019
Accepted: 28 August 2020
First Online: 2 September 2020
Compliance with ethical standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the trial.
: Y.A. has received honoraria from Chugai Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Meiji Seika Pharma Co. Ltd., and Kyowa Hakko Kirin Co., Ltd. N.A. has received honoraria from SRL, Inc. and Nippon-Shinyaku Co., Ltd., and research funds from Chugai Pharmaceutical Co., Ltd. N.D. has received research funds from Fujimoto Pharmaceutical Co. and scholarship endowments from Pfizer Japan Inc. A.T. has received honoraria and research funds from Chugai Pharmaceutical Co., Ltd., and research funds from Kyowa Hakko Kirin Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Y.K. has received honoraria from Astellas Pharma Inc. H.K. has received honoraria from Bristol-Myers Squibb, Astellas Pharma Inc., and Novartis Pharma K.K., and consulting fees from Astellas Pharma Inc., Amgen Astellas BioPharma K.K., and Daiichi Sankyo Co., Ltd., and research funds from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., and Celgene Corporation. I.M. has received honoraria from Pfizer Japan Inc., research funds from Chugai Pharmaceutical Co., Ltd., and scholarship endowments from Chugai Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. Y.M. has honoraria from Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd., and scholarship endowments from Chugai Pharmaceutical Co., Ltd. The other authors have no conflict of interest.